| Literature DB >> 26893303 |
Shannon Dallas1, Laurent Salphati2, David Gomez-Zepeda1, Thomas Wanek1, Liangfu Chen1, Xiaoyan Chu1, Jeevan Kunta1, Mario Mezler1, Marie-Claude Menet1, Stephanie Chasseigneaux1, Xavier Declèves1, Oliver Langer1, Esaie Pierre1, Karen DiLoreto1, Carolin Hoft1, Loic Laplanche1, Jodie Pang1, Tony Pereira1, Clara Andonian1, Damir Simic1, Anja Rode1, Jocelyn Yabut1, Xiaolin Zhang1, Nico Scheer1.
Abstract
Breast cancer resistance protein (BCRP) is expressed in various tissues, such as the gut, liver, kidney and blood brain barrier (BBB), where it mediates the unidirectional transport of substrates to the apical/luminal side of polarized cells. Thereby BCRP acts as an efflux pump, mediating the elimination or restricting the entry of endogenous compounds or xenobiotics into tissues and it plays important roles in drug disposition, efficacy and safety. Bcrp knockout mice (Bcrp(-/-)) have been used widely to study the role of this transporter in limiting intestinal absorption and brain penetration of substrate compounds. Here we describe the first generation and characterization of a mouse line humanized for BCRP (hBCRP), in which the mouse coding sequence from the start to stop codon was replaced with the corresponding human genomic region, such that the human transporter is expressed under control of the murineBcrppromoter. We demonstrate robust human and loss of mouse BCRP/Bcrp mRNA and protein expression in the hBCRP mice and the absence of major compensatory changes in the expression of other genes involved in drug metabolism and disposition. Pharmacokinetic and brain distribution studies with several BCRP probe substrates confirmed the functional activity of the human transporter in these mice. Furthermore, we provide practical examples for the use of hBCRP mice to study drug-drug interactions (DDIs). The hBCRP mouse is a promising model to study the in vivo role of human BCRP in limiting absorption and BBB penetration of substrate compounds and to investigate clinically relevant DDIs involving BCRP.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26893303 DOI: 10.1124/mol.115.102079
Source DB: PubMed Journal: Mol Pharmacol ISSN: 0026-895X Impact factor: 4.436